In Vivo Cell Therapy
Multiple Myeloma
About GigaMune
GigaMune is an early-stage biotech pioneering a novel approach to cell therapy by developing in vivo treatments, eliminating the need for ex vivo cell manufacturing. The company leverages a proprietary technology platform combining powerful bioinformatics algorithms, high-throughput genomics, and artificial intelligence to design targeted viral delivery vectors and therapeutic CAR constructs. Its initial pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease. Founded by serial entrepreneurs and backed by multiple SBIR grants, GigaMune is positioned to address significant access and scalability challenges in the cell therapy field.
View full company profileAbout GigaMune
GigaMune is an early-stage biotech pioneering a novel approach to cell therapy by developing in vivo treatments, eliminating the need for ex vivo cell manufacturing. The company leverages a proprietary technology platform combining powerful bioinformatics algorithms, high-throughput genomics, and artificial intelligence to design targeted viral delivery vectors and therapeutic CAR constructs. Its initial pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease. Founded by serial entrepreneurs and backed by multiple SBIR grants, GigaMune is positioned to address significant access and scalability challenges in the cell therapy field.
View full company profileAbout GigaMune
GigaMune is an early-stage biotech pioneering a novel approach to cell therapy by developing in vivo treatments, eliminating the need for ex vivo cell manufacturing. The company leverages a proprietary technology platform combining powerful bioinformatics algorithms, high-throughput genomics, and artificial intelligence to design targeted viral delivery vectors and therapeutic CAR constructs. Its initial pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease. Founded by serial entrepreneurs and backed by multiple SBIR grants, GigaMune is positioned to address significant access and scalability challenges in the cell therapy field.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |
| Sequesta™ | ID4Pharma | Pre-clinical |